Archive | November, 2014

Life Science Nation and FreeMind Group Align In San Francisco for Early Stage Fundraising Executives

26 Nov

By Dennis Ford, Founder & CEO, LSN

Dennis bookToday, Life Science Nation (LSN) accelerates the funding of early stage life science firms via a sourcing platform for private investment, making CEOs more efficient in their capital raising efforts. The FreeMind Group (FMG) specializes in assisting life science organizations secure non-dilutive funding from US Federal Agencies and Private Foundations. LSN and FMG are experts in early stage private and non-dilutive funding respectively, and this complementary expertise fully supports the early stage financing needs of life science entrepreneurs.  As both of these financing sources are vital to early-stage financing, CEOs benefit from understanding both domains:  LSN’s 10 categories of private early stage and FMG’s governmental non-dilutive funding.

LSN and FMG have been working side by side for years, and recently saw that combining both pools of attendees at their respective conferences could transform each from a one-day event into a two-day conference offering dynamic partnering and compelling financing content to the early-stage CEOs visiting San Francisco during the JP Morgan Healthcare Conference.

Dennis Ford, CEO, LSN, stated “FreeMind and LSN give scientist entrepreneurs a 360 degree view of all the funding options available today.  Both the private and governmental capital landscape has morphed over recent years and I think this is a fabulous opportunity to help early stage CEOs get up to speed on both financing options. A savvy entrepreneur will go after all the capital available to them, both non-dilutive and private.  Indeed, most early stage companies already have a hybrid of each type of funding.  It’s part of the early stage gestalt.”

Ram May-Ran, Managing Partner, FMG, explained “Raising capital is fundamentally a numbers game.  Each financing option needs to be thoroughly explored, and that means both private and non-dilutive.”  Ram went on to say that many government funders offer matching funds for private capital brought into a company.  “It makes total sense for the CEOs to investigate and become knowledgeable on all the funding alternatives as this can greatly reduce the time spent raising capital.”

LSN owns and operates the Redefining Early Stage Investments (RESI) conference series.  The next RESI will be held on January 13th in San Francisco, at the Marines’ Memorial Club and Hotel. FMG owns and operates the Non-Dilutive Funding Summit, which will be held on January 14th in San Francisco at the Nikko Hotel. By virtually connecting these two events, attendees at LSN’s RESI will automatically be registered for FMG’s Non-Dilutive Funding Summit, and in turn Summit attendees will be able to get a discount coupon to register for RESI.  Executives from each firm agree that this may become an ongoing relationship, as creating these venues for partnering and fundraising can support a groundswell to aid in the commercialization of science.

For more information on LSN and RESI:

For more information on FMG and Non-Dilutive Funding Summit:

A Thanksgiving Mandate Cornucopia

26 Nov

By Lucy Parkinson, Senior Research Manager, LSN

lucy 10*10Here at LSN, we’re getting ready to go home for Thanksgiving.  But first, we’d like to thank all our readers, supporters and friends across the global life science industry.  We wouldn’t be here without you.

In the spirit of the season, LSN Research welcomes you to the table to share the mandates we’ve gathered from our recent conversations with investors across the world.  This cornucopia of investors are from 6 different nations, and cover every niche of the life science sector – from agriculture to therapeutics to devices to healthcare IT.

Click on the mandates below to see what’s cooking in the rest of the world

  1. Private Equity Firm Seeks AgBio and Sustainable Bio Opportunities
  2. Early Stage VC Seeks Healthcare IT Opportunities
  3. Global Firm With Patient-Centric Strategy Invests In Oncology, Cardiovascular, Anti-infectives, CNS/pain, and Women’s Health
  4. Taiwan-based VC Investing In Innovative Early-Stage Medtech 
  5. South American Corporate VC Interested in Orphan Drugs
  6. UK-based Fund Group Seeks Medical Devices, Diagnostics, Lab Equipment, and Healthcare IT
  7. Cross-Border VC Looking At Healthcare Technology for Emerging Markets 
  8. Global Health Organization Funds Diagnostics, Vaccines and Women’s Health
  9. European PE Invests in Drug Development, Diagnostics, and Medical Devices
  10. Dutch Firm Investing In Medtech, Healthcare IT, and Biotech R&D Services

Hot Life Science Investor Mandate 1: Private Equity Firm Seeks AgBio and Sustainable Bio Opportunities

26 Nov

A venture capital and private equity firm based in California makes equity allocations in advanced biotechnologies such as synthetic biology. The firm is currently seeking opportunities globally.

The firm manages a fund that identifies compelling investment strategies in/around advanced biotechnologies. The fund focuses on scalable, portable and sustainable technologies within high human-imperative sectors such as agriculture-food, energy-resources, industrial chemicals-materials, water-environment, and defense-space. Medical and healthcare-related technology is not of interest at this point. When it comes to development phases, the fund is stage-agnostic and considers from seed and venture stage projects to on-market projects.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 2: Early Stage VC Seeks Healthcare IT Opportunities

26 Nov

An early stage venture firm based in New York is investing from its third fund, which closed in 2013. The firm looks to invest in the Healthcare IT sector, and the initial investment size can range from $250k to $10million. The firm typically invests in companies at Seed and Series A stages.

The firm will consider companies across the US, and is currently looking for new opportunities in the Healthcare IT sectors. The firm will not consider devices or biotech companies. In the Healthcare IT sector, the firm is most interested in companies that do not need FDA approvals and focus on data, analytics, Internet, vertical applications and solutions. Historically, the firm was active in companies developing analytical platform, bioinformatics and software used in the pharmaceutical supply chain.

The firm primarily invests in pre-revenue companies, and prefers to invest in companies with a strong management team and significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 3: Global Firm With Patient-Centric Strategy Invests In Oncology, Cardiovascular, Anti-infectives, CNS/pain, and Women’s Health

26 Nov

A global healthcare investment firm, headquartered in New York, is investing from an evergreen Life Sciences investment fund.

Typical allocations are up to $5M in early stage projects and $10-15M in late stage projects. With follow-on allocations, the total investment can reach up to $30M per company. The firm takes a mid- to long-term investment approach. The firm leverages flexible capital structures and can invest in both private and public companies. The firm often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities with 80% focus on US and Canada and 20% on Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric.

The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which help women give birth to healthy children.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 4: Taiwan-based VC Investing In Innovative Early-Stage Medtech  

26 Nov

A venture capital firm based in Taipei, Taiwan, solely invests in early stage medical technology ventures. The firm currently manages a fund which was raised in 2012 and closed at USD 100 million. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 5: South American Corporate VC Interested in Orphan Drugs

26 Nov

A strategic investment fund formed by a South America-based pharma company is seeking to invest in biotech companies.  For early-stage opportunities the fund typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities the fund is more likely to form strategic partnerships that involve rights to an asset.  The fund is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

The fund invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities.  Drug-device combinations will also be considered, but not diagnostics.  The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas.  It is preferred that indications have validated clinical endpoints and can be studied using small trials.  Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email